veftags.blogg.se

Samples for ER and PgR testing are fixed in 10% NBF for 6 to 72 hours. Time from tissue acquisition to fixation should be as short as possible.

Interpreters have method to maintain consistency and competency documented regularly.Īccession slip and report must include guideline-detailed elements. Negative ER or PgR requires < 1% of tumor cells with ER or PgR staining. H score, Allred score, or Quick score may be provided. Image analysis is a desirable method of quantifying percentage of tumor cells that are immunoreactive. Both average intensity and extent of staining are reported. Positive ER or PgR requires that ≥ 1% of tumor cells are immunoreactive. Interpretation follows guideline recommendation. Sample has prolonged cold ischemia time or fixation duration 72 hours and is negative on testing in the absence of internal control elements. Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT Washington University School of Medicine, St Louis, MO American Society of Clinical Oncology, Alexandria, VA University of Michigan Comprehensive Cancer Center, University of Michigan Health System St Joseph Mercy Hospital Gemini Group, Ann Arbor Advanced Diagnostics Laboratory, Redford, MI Presbyterian Hospital, Charlotte, NC Indiana University, Bloomington, IN St Jude Medical Center, Fullerton, CA University of Rochester, Rochester, NY Brigham and Women’s Hospital, Boston, MA National Cancer Institute, Bethesda ST Consulting, Glen Echo The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Ohio State University, Columbus, OH Baylor College of Medicine, Houston, TX National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA The Delta Pathology Group, Shreveport, LA University of Louisville, Louisville, KY Royal Marsden Hospital, London United Kingdom National External Quality Assessment Service, Sheffield University of West of England, Bristol, United Kingdom Princess Alexandra Hospital, Brisbane, Queensland, Australia University of British Columbia, Vancouver, British Columbia Royal University Hospital, Saskatoon, Saskatchewan, Canada Tohoku University School of Medicine, Sendai, Japan Radboud University, Nijmegen, the Netherlands and European Institute of Oncology and University of Milan, Milan, Italy.